Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

59.19 +1.84 (+3.22%)
Streaming Delayed Price Updated: 3:28 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,283,060
Open 59.47
Bid (Size) 59.18 (1,100)
Ask (Size) 59.19 (200)
Prev. Close 57.34
Today's Range 58.78 - 60.64
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 1.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive... 
Via MarketMinute
News headline image
The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance
As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company... 
Via MarketMinute
Topics Economy

Performance

YTD
+13.0%
+13.0%
1 Month
+27.7%
+27.7%
3 Month
+0.9%
+0.9%
6 Month
-16.7%
-16.7%
1 Year
-30.9%
-30.9%

More News

Read More
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
3 of the Best Stocks Under $100 to Buy in 2026 ↗
Via The Motley Fool
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗
Via Stocktwits
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
Via MarketMinute
Topics Economy
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
News headline image
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
Via MarketMinute
Topics Economy
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗
Via The Motley Fool
News headline image
Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗
Via Stocktwits
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
Via Stocktwits
News headline image
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗
Via Stocktwits
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
Via The Motley Fool
News headline image
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗
Via The Motley Fool
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
Via MarketMinute
Topics Intellectual Property
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
Via PredictStreet
Topics Economy Lawsuit World Trade
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗
Via MarketBeat

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 59.19
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 01/09/26 03:28 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.